Amerise Biosciences
AMARDEEPINDUSTRIESLTD NSE
Amerise Biosciences
Industrial ProductsNSE: AMARDEEPINDUSTRIESLTD BSE: 531681 Plastic Products - Industrial
Key Fundamentals
MicrocapPlastic Products - IndustrialIndustrial ProductsMarket Cap
₹5.40 Cr
Volatility
Moderate
P/E Ratio
-82
EBITDA
₹-0.23 Cr
Return on Equity
0.11%
Debt to Equity
0
Book Value
₹0.82
EPS
₹0
52W High
₹1.03
52W Low
₹0.5
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company is almost debt free.
- Stock is trading at 1.02 times its book value
Weaknesses
2- Company has low interest coverage ratio.
- Company has a low return on equity of -0.74% over last 3 years.
Growth Rate
Revenue Growth
-100% lower than
3Y
Net Income Growth
-200% lower than
3Y
Cash Flow Change
—
ROE
-104% lower than
3Y
ROCE
-105% higher than
3Y
EBITDA Margin (Avg.)
-100% level than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0.04 | 0 | 0 | 0 | 0.19 | 0.06 | 0.07 | 0.04 | 0.08 | 0 |
| Expenses | 0.07 | 0.04 | 0.06 | 0.02 | 0.05 | 0.03 | 0.02 | 0.08 | 0.07 | 0.11 | 0.03 | 0.02 | 0.08 |
| Operating Profit | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 | 0.06 | -0.08 |
| OPM % | — | — | — | 50% | — | — | — | 57.89% | -16.67% | -57.14% | 25% | 75% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 | 0.06 | -0.08 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.07 | -0.04 | -0.06 | 0.02 | -0.05 | -0.03 | -0.02 | 0.11 | -0.01 | -0.04 | 0.01 | 0.06 | -0.08 |
| EPS in Rs | -0.01 | -0.01 | -0.01 | 0 | -0.01 | 0 | 0 | 0.02 | 0 | -0.01 | 0 | 0.01 | -0.01 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 1.18 | 0 | 0 | 9.58 | 0.01 | 0.04 | 0.19 | 0.26 | 0.19 |
| Expenses | 0.05 | 0.03 | 0.94 | 0.02 | 1.18 | 0.15 | 0.17 | 9.03 | 0.13 | 0.19 | 0.18 | 0.24 | 0.24 |
| Operating Profit | -0.05 | -0.03 | -0.94 | -0.02 | 0 | -0.15 | -0.17 | 0.55 | -0.12 | -0.15 | 0.01 | 0.02 | -0.05 |
| OPM % | — | — | — | — | 0% | — | — | 5.74% | -1200% | -375% | 5.26% | 7.69% | -26.32% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | -0.17 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | -0.05 | -0.03 | -0.94 | -0.02 | 0 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.02 | -0.05 |
| Tax % | 0% | 0% | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
| Net Profit | -0.05 | -0.03 | -0.94 | -0.02 | 0 | -0.15 | -0.34 | 0.55 | -0.12 | -0.15 | 0.01 | 0.02 | -0.05 |
| EPS in Rs | -0.01 | 0 | -0.14 | 0 | 0 | -0.02 | -0.05 | 0.08 | -0.02 | -0.02 | 0 | 0 | -0.01 |
| Div. Payout % | 0% | 0% | 0% | 0% | — | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| Reserves | -0.05 | -0.07 | -1.01 | -1.03 | -1.03 | -1.18 | -1.52 | -0.97 | -1.09 | -1.23 | -1.23 | -1.21 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.08 | 0.09 | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0.04 | 0.01 | 0.02 | 0.6 | 0.54 | 6.27 | 0.04 | 0.01 | 3.08 | 2.02 |
| Total Liabilities | 6.56 | 6.54 | 5.64 | 5.59 | 5.6 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 7.42 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 4.82 | 5.89 | 2.34 | 2.31 | 0.54 | 5.37 | 3.04 | 4.69 | 4.57 | 2.27 | 2.38 | 3.77 |
| Other Assets | 1.74 | 0.65 | 3.3 | 3.28 | 5.06 | 0.66 | 2.59 | 7.3 | 1.08 | 3.12 | 6.08 | 3.65 |
| Total Assets | 6.56 | 6.54 | 5.64 | 5.59 | 5.6 | 6.03 | 5.63 | 11.99 | 5.65 | 5.39 | 8.46 | 7.42 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 0.27 | 1.08 | -3.56 | -0.04 | -1.78 | 4.89 | -0.39 | 0.06 | -0.13 | -0.17 | 3.07 | -1.06 |
| Investing | 0.32 | -1.07 | 3.55 | 0.03 | 1.77 | -4.89 | 0.39 | -0.15 | 0.13 | 0.27 | -3.07 | 1.63 |
| Financing | -0.59 | 0 | 0 | 0 | 0 | 0 | 0 | 0.08 | 0.01 | -0.09 | 0 | 0 |
| Net Cash Flow | 0 | 0 | -0.01 | -0.01 | -0.01 | 0.01 | -0.01 | -0.01 | 0 | 0.01 | 0 | 0.57 |
| Free Cash Flow | 0.27 | 1.08 | -3.56 | -0.04 | -1.78 | 4.89 | -0.39 | 0.06 | -0.13 | -0.17 | 3.07 | -1.06 |
| CFO/OP | -540 | -3,600 | 379 | 200 | — | -3,260 | 229 | 11 | 108 | 113 | 30,700 | -5,300 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | — | — | — | — | 1,383 | — | — | 237 | 0 | 0 | 0 | 0 |
| Inventory Days | — | — | — | — | 0 | — | — | 0 | — | — | — | — |
| Cash Conversion Cycle | — | — | — | — | 1,383 | — | — | 237 | 0 | 0 | 0 | 0 |
| Working Capital Days | — | — | — | — | 1,376 | — | — | -1.91 | -1,460 | -183 | -5,898 | -2,822 |
| ROCE % | -0.73% | -0.46% | -15.49% | -0.36% | 0% | -2.72% | -6.46% | 10.18% | -2.12% | -2.73% | 0.19% | 0.37% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Amerise Biosciences insights
56 extracted metrics + investor summaries across FY09–FY26.
Documents
2
Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2026 And Outcome Of The Board Meeting Held On Tuesday 5Th May 2026.
5 May - Board approved audited FY26 results; net profit Rs 1.61 lakh, audit report unmodified. 5 May - Board approved audited FY26 results; net profit Rs 1.61 lakh, audit report unmodified.
Frequently Asked Questions about Amerise Biosciences
What does Amerise Biosciences Ltd do?
Incorporated in 1984, Amerise Biosciences Ltd specializes in NDA, 505(b)(2), and complex
formulations.[1]
Where is Amerise Biosciences Ltd (531681) listed?
Amerise Biosciences Ltd trades as AMARDEEPINDUSTRIESLTD on the NSE and under code 531681 on the BSE.
Which sector does Amerise Biosciences Ltd belong to?
Amerise Biosciences Ltd is classified under the Industrial Products sector, in the Plastic Products - Industrial industry.
What is the market capitalisation of Amerise Biosciences Ltd?
Amerise Biosciences Ltd has a market capitalisation of ₹5.4 Cr, which places it in the Small Cap band.
What is the PE ratio of Amerise Biosciences Ltd?
Amerise Biosciences Ltd trades at a PE ratio of -82.00, on earnings per share of ₹0, against a book value of ₹0.82 per share.
What is the 52-week high and low of Amerise Biosciences Ltd?
Over the last 52 weeks Amerise Biosciences Ltd has traded between ₹0.5 and ₹1.03.
What is the Return on Equity (ROE) of Amerise Biosciences Ltd?
Amerise Biosciences Ltd reported a return on equity of 0.11%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1984, Amerise Biosciences Ltd specializes in NDA, 505(b)(2), and complex formulations.[1]
Website amerisebiosciencesltd.life
Face Value ₹ 1
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531681.md for Amerise Biosciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.